JP2023517794A5 - - Google Patents

Info

Publication number
JP2023517794A5
JP2023517794A5 JP2022541840A JP2022541840A JP2023517794A5 JP 2023517794 A5 JP2023517794 A5 JP 2023517794A5 JP 2022541840 A JP2022541840 A JP 2022541840A JP 2022541840 A JP2022541840 A JP 2022541840A JP 2023517794 A5 JP2023517794 A5 JP 2023517794A5
Authority
JP
Japan
Prior art keywords
sequence
seq
lcvr
antigen
hcvr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022541840A
Other languages
English (en)
Japanese (ja)
Other versions
JP7801225B2 (ja
JP2023517794A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/012197 external-priority patent/WO2021141907A1/en
Publication of JP2023517794A publication Critical patent/JP2023517794A/ja
Publication of JP2023517794A5 publication Critical patent/JP2023517794A5/ja
Application granted granted Critical
Publication of JP7801225B2 publication Critical patent/JP7801225B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022541840A 2020-01-06 2021-01-05 抗tnfr2抗体及びその使用 Active JP7801225B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062957543P 2020-01-06 2020-01-06
US62/957,543 2020-01-06
US202063041234P 2020-06-19 2020-06-19
US63/041,234 2020-06-19
PCT/US2021/012197 WO2021141907A1 (en) 2020-01-06 2021-01-05 Anti-tnfr2 antibody and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026000292A Division JP2026132361A (ja) 2020-01-06 2026-01-05 抗tnfr2抗体及びその使用

Publications (3)

Publication Number Publication Date
JP2023517794A JP2023517794A (ja) 2023-04-27
JP2023517794A5 true JP2023517794A5 (cg-RX-API-DMAC7.html) 2024-01-15
JP7801225B2 JP7801225B2 (ja) 2026-01-16

Family

ID=74236316

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022541840A Active JP7801225B2 (ja) 2020-01-06 2021-01-05 抗tnfr2抗体及びその使用

Country Status (10)

Country Link
US (2) US12617860B2 (cg-RX-API-DMAC7.html)
EP (1) EP4087874A1 (cg-RX-API-DMAC7.html)
JP (1) JP7801225B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230020379A (cg-RX-API-DMAC7.html)
CN (1) CN115996950A (cg-RX-API-DMAC7.html)
AU (1) AU2021206618A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022013424A2 (cg-RX-API-DMAC7.html)
CA (1) CA3166898A1 (cg-RX-API-DMAC7.html)
TW (1) TWI867138B (cg-RX-API-DMAC7.html)
WO (1) WO2021141907A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115925929A (zh) * 2021-09-22 2023-04-07 上海康岱生物医药技术股份有限公司 抗tnfr2单克隆抗体及其应用
CN118922531A (zh) 2022-03-28 2024-11-08 高诚生物医药公司 预测性应答生物标志物发现方法
WO2026022721A1 (en) * 2024-07-26 2026-01-29 Janssen Biotech, Inc. Anti-tnfr2 antibodies
WO2026119935A1 (en) 2024-12-03 2026-06-11 Resano Gmbh Combination comprising a tumor necrosis factor receptor 2 agonist
WO2026119926A1 (en) 2024-12-03 2026-06-11 Resano Gmbh Agonist polypeptide for use in treating and/or preventing heart failure

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
AU6366999A (en) 1998-10-30 2000-05-22 Takeda Chemical Industries Ltd. Betacellulin protein-containing preparations
US6900292B2 (en) 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
KR100976076B1 (ko) 2003-05-22 2010-08-17 아보트 러보러터리즈 인다졸, 벤즈이속사졸 및 벤즈이소티아졸 키나제 억제제
DK1678314T3 (da) 2003-10-22 2012-12-03 Keck Graduate Inst Fremgangsmåde til syntetisering af heteromultimere polypeptider i gær ved anvendelse af en haploid parringsstrategi
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
WO2006076288A2 (en) 2005-01-11 2006-07-20 Five Prime Therapeutics, Inc. Dna constructs for long-term expression of intravascularly injected naked dna
JP5238936B2 (ja) 2005-03-25 2013-07-17 ジーアイティーアール,インク. Gitr結合分子およびその使用
DK1879573T3 (da) 2005-05-10 2013-02-25 Incyte Corp Modulatorer af indolamin 2,3-dioxygenase og fremgangsmåder til anvendelse deraf
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
ES2540561T3 (es) 2005-12-20 2015-07-10 Incyte Corporation N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa
CA2663057C (en) 2006-09-19 2015-12-08 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
PT2175884T (pt) 2007-07-12 2016-09-21 Gitr Inc Terapias de combinação empregando moléculas de ligação a gitr
US7981415B2 (en) 2007-09-07 2011-07-19 Cisthera, Inc. Humanized PAI-1 antibodies
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
WO2009073620A2 (en) 2007-11-30 2009-06-11 Newlink Genetics Ido inhibitors
EP2296789A1 (fr) 2008-05-29 2011-03-23 Saint-Gobain Centre de Recherches et d'Etudes Européen Structure en nid d'abeille a base de titanate d'aluminium
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
IN2015DN02826A (cg-RX-API-DMAC7.html) 2009-09-03 2015-09-11 Merck Sharp & Dohme
EP2493862B1 (en) 2009-10-28 2016-10-05 Newlink Genetics Corporation Imidazole derivatives as ido inhibitors
CN102918061B (zh) 2010-03-05 2016-06-08 霍夫曼-拉罗奇有限公司 针对人csf-1r的抗体及其用途
NZ729044A (en) 2010-09-09 2020-07-31 Pfizer 4-1bb binding molecules
NO2694640T3 (cg-RX-API-DMAC7.html) 2011-04-15 2018-03-17
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
MX356337B (es) 2011-12-15 2018-05-23 Hoffmann La Roche Anticuerpos contra csf-1r humano y sus usos.
MX2014008961A (es) 2012-02-06 2014-10-14 Genentech Inc Composiciones y metodos para utilizar inhibidores de csf1r.
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
KR20150018533A (ko) 2012-05-11 2015-02-23 파이브 프라임 테라퓨틱스, 인크. 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
CN107759690A (zh) 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
JP6367836B2 (ja) * 2013-02-07 2018-08-01 ザ ジェネラル ホスピタル コーポレイション T制御性細胞の増殖または枯渇方法
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
DK3447075T3 (da) * 2015-05-15 2023-11-13 Massachusetts Gen Hospital Antagonistiske antistoffer af antitumornekrosefaktorreceptor-superfamilien
WO2017040312A1 (en) 2015-08-28 2017-03-09 The General Hospital Corporation Agonistic anti-tumor necrosis factor receptor 2 antibodies
MX2018006072A (es) * 2015-11-19 2018-08-01 Squibb Bristol Myers Co Anticuerpos contra receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos.
KR20250007678A (ko) * 2016-05-13 2025-01-14 더 제너럴 하스피탈 코포레이션 길항성 항-종양 괴사 인자 수용체 슈퍼패밀리 항체
US11389480B2 (en) * 2017-05-19 2022-07-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibody targeting TNFR2 for cancer immunotherapy
WO2019094559A2 (en) 2017-11-09 2019-05-16 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides
US20210371537A1 (en) 2018-09-18 2021-12-02 Merrimack Pharmaceuticals, Inc. Anti-tnfr2 antibodies and uses thereof
CN113874083A (zh) 2019-03-01 2021-12-31 梅里麦克制药股份有限公司 抗-tnfr2抗体及其用途
EP3907240A4 (en) 2019-08-02 2023-02-22 Jiangsu Simcere Pharmaceutical Co., Ltd. ANTI-TNFR2 ANTIBODIES AND USE THEREOF
AU2020348224A1 (en) 2019-09-17 2022-05-12 Apexigen, Inc. Anti-TNFR2 antibodies and methods of use
CN112480259B (zh) 2021-02-05 2021-05-04 百奥赛图(北京)医药科技股份有限公司 抗tnfr2抗体及其用途

Similar Documents

Publication Publication Date Title
JP2022533538A5 (cg-RX-API-DMAC7.html)
JP2021534096A5 (cg-RX-API-DMAC7.html)
JP2020521448A5 (cg-RX-API-DMAC7.html)
JP2021533726A5 (cg-RX-API-DMAC7.html)
JP2014158469A5 (cg-RX-API-DMAC7.html)
US20230303691A1 (en) Neutralization of inhibitory pathways in lymphocytes
JP2018510636A5 (cg-RX-API-DMAC7.html)
JP2017535257A5 (cg-RX-API-DMAC7.html)
JP2020520370A5 (cg-RX-API-DMAC7.html)
JP2021510521A5 (cg-RX-API-DMAC7.html)
RU2019116624A (ru) Новые анти_cd137 антитела и их применение
JP2019513701A5 (cg-RX-API-DMAC7.html)
JP2023549537A5 (cg-RX-API-DMAC7.html)
JP2015509947A5 (cg-RX-API-DMAC7.html)
JP2024016024A5 (cg-RX-API-DMAC7.html)
JP2023540526A5 (cg-RX-API-DMAC7.html)
CN110799543A (zh) 肝细胞癌的免疫治疗
RU2013125459A (ru) АНТИТЕЛА ПРОТИВ БЕЛКА РЕЦЕПТОРА c-Met
JP2020522473A5 (cg-RX-API-DMAC7.html)
JP2021523140A5 (cg-RX-API-DMAC7.html)
JP2023518153A5 (cg-RX-API-DMAC7.html)
JP2024527576A5 (cg-RX-API-DMAC7.html)
IL276675B2 (en) Anti-PD-1 antibodies and uses thereof
CN112351794A (zh) 用于尿路上皮癌的免疫治疗方法
JP2021525806A5 (cg-RX-API-DMAC7.html)